Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
About Atara Biotherapeutics (ATRA)
Atara Biotherapeutics, Inc. is a pioneering biotechnology company dedicated to developing transformative therapies for patients suffering from serious diseases, including solid tumors, hematologic cancers, and autoimmune conditions. Founded in 2012, the company is named after Atara Ciechanover, whose battle with cancer inspired its mission to empower patients with innovative treatment options. Atara operates in the United States healthcare sector and focuses on advancing cellular immunotherapy platforms to address significant unmet medical needs.
Core Business Areas
Atara specializes in the development of allogeneic T-cell immunotherapies, leveraging groundbreaking research into the role of T-cells and growth factors such as activin and myostatin in disease progression. The company’s product pipeline is centered on addressing the underlying mechanisms of diseases, offering novel solutions for patients with limited or no effective treatment options. Atara’s key areas of focus include:
- Epstein-Barr Virus (EBV)-Targeted Therapies: Leveraging EBV-specific cytotoxic T lymphocytes (CTLs) to treat diseases associated with EBV, including post-transplant lymphoproliferative disease (PTLD).
- CAR-T Cell Therapy: Developing next-generation chimeric antigen receptor (CAR) T-cell therapies, such as ATA3219, to target hematologic malignancies.
- Multiple Sclerosis (MS) and Autoimmune Diseases: Investigating innovative therapies like ATA188 to address progressive forms of MS by targeting EBV-infected B-cells implicated in autoimmune pathogenesis.
Product Pipeline
Atara’s robust pipeline includes several promising product candidates designed to address critical gaps in current medical treatments:
- Tab-cel®: An allogeneic EBV-specific T-cell immunotherapy targeting EBV-associated cancers, currently in advanced clinical trials.
- ATA188: A groundbreaking therapy aimed at treating progressive multiple sclerosis by modulating immune responses to EBV-infected cells.
- ATA3219: A CAR-T platform designed to enhance the efficacy and safety of T-cell therapies for hematologic cancers.
These therapies reflect Atara’s commitment to addressing both rare and prevalent diseases through innovative approaches rooted in cellular biology and immunotherapy.
Collaborations and Research Partnerships
Atara’s strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) underscores its commitment to advancing T-cell immunotherapy research. This partnership focuses on the development of three T-cell product candidates targeting EBV, cytomegalovirus (CMV), and Wilms Tumor 1 (WT1). By combining Atara’s expertise in immunotherapy with MSK’s research capabilities, the company aims to accelerate the development of groundbreaking treatments for cancer and other diseases.
Competitive Landscape
Atara operates in a highly competitive biotechnology landscape, with key competitors including companies specializing in CAR-T therapies, allogeneic cell therapies, and advanced biologics. However, Atara differentiates itself through its focus on allogeneic T-cell platforms, which offer potential advantages in scalability, manufacturing, and cost-effectiveness compared to autologous therapies. Additionally, its emphasis on EBV-targeted therapies positions it uniquely within the immunotherapy space, addressing both oncology and autoimmune indications.
Challenges and Opportunities
While Atara faces challenges such as navigating complex regulatory pathways, achieving clinical trial success, and competing in a crowded biotech market, it also has significant opportunities to establish itself as a leader in allogeneic immunotherapy. By addressing high unmet medical needs and leveraging its innovative pipeline, Atara has the potential to transform treatment paradigms for a range of serious diseases.
Conclusion
Atara Biotherapeutics is at the forefront of cellular immunotherapy, driven by a mission to empower patients with better treatment options. Through its innovative product pipeline, strategic collaborations, and focus on addressing unmet medical needs, Atara is poised to make a meaningful impact in the biotechnology industry. Its commitment to advancing science and improving patient outcomes underscores its significance as a key player in the healthcare sector.
Atara Biotherapeutics (NASDAQ: ATRA) has announced the grant of 33,150 restricted stock units and 13,375 stock options to newly hired employees, aimed at incentivizing talent. The restricted stock units will vest over four years, while the stock options have a ten-year term with an exercise price set at $4.40. This action aligns with Nasdaq Listing Rule 5635(c)(4) to attract employees critical for the company's focus on T-cell immunotherapy. Atara continues to push forward its EBV T-cell platform for treating serious diseases.
Atara Biotherapeutics (NASDAQ: ATRA) announced that its CEO, Pascal Touchon, will engage in a virtual fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on November 30, 2022, at 2:15 p.m. EST. The event will focus on Atara's advancements in T-cell immunotherapy, particularly its allogeneic Epstein-Barr virus (EBV) T-cell platform. Attendees can access a live webcast on atarabio.com, with an archived version available for 30 days post-event.
Atara Biotherapeutics (NASDAQ: ATRA) announced that its Chief Medical Officer, AJ Joshi, and Chief Financial Officer, Utpal Koppikar, will participate in a fireside chat at the Stifel Healthcare Conference in New York on November 16, 2022, at 1:50 p.m. EST. A live webcast will be available on atarabio.com, with an archived replay accessible for 30 days. Atara is pioneering T-cell immunotherapy targeting conditions like cancer and autoimmune diseases, leveraging its unique allogeneic Epstein-Barr virus T-cell platform.
Atara Biotherapeutics reported significant progress in T-cell immunotherapy, highlighted by a positive CHMP opinion for its product Ebvallo™ for treating EBV+ PTLD. The EMA's endorsement positions it as the first allogeneic T-cell therapy potentially approved by the end of 2022. Financially, Atara reported a net loss of $84.1 million, with cash reserves of $265.4 million as of September 30, 2022. The company also presented promising data on ATA188 for progressive MS, showing less brain atrophy and potential remyelination. A conference call is scheduled for November 8, 2022.
Atara Biotherapeutics (NASDAQ: ATRA) has granted 7,200 restricted stock units to two new employees, approved by its Compensation Committee under the 2018 Inducement Plan. The grant date was November 1, 2022. The stock units vest over four years, with 25% vesting after the first anniversary and the remainder vesting quarterly. This action complies with Nasdaq Listing Rule 5635(c)(4). Atara focuses on T-cell immunotherapy, developing therapies for cancer and autoimmune diseases, and is advancing multiple programs targeting serious diseases.
Atara Biotherapeutics (NASDAQ: ATRA) will announce its third quarter 2022 financial results on November 8, 2022, after market close. A live conference call and webcast will follow at 4:30 p.m. EST, where the company will discuss financial results and corporate updates. Atara is a leader in T-cell immunotherapy, focusing on allogeneic Epstein-Barr virus (EBV) T-cell platforms for treating cancer and autoimmune diseases. The company is advancing multiple therapies, with a promising pipeline including tab-cel, currently in Phase 3 development for EBV-driven post-transplant lymphoproliferative disease.
Atara Biotherapeutics (ATRA) announced promising results regarding ATA188, targeting progressive multiple sclerosis (MS), with data presented at the ECTRIMS congress. In an open-label extension study, 29% of patients (7 of 24) achieved confirmed disability improvement (CDI) over 46 months. Longitudinal MRI analysis indicates less brain atrophy and potential remyelination linked to ATA188 treatment. The therapy remains well tolerated with no severe adverse effects reported. Further data will be presented at the congress on October 26, highlighting ATA188's potential impact on MS treatment.
Atara Biotherapeutics (NASDAQ: ATRA) and Pierre Fabre announced a positive opinion from the CHMP recommending the approval of EbvalloTM (tabelecleucel) for treating relapsed or refractory EBV+ PTLD in patients aged two and older. This decision is based on the pivotal Phase 3 ALLELE study, demonstrating a favorable risk-benefit profile. The European Commission's approval is expected in Q4 2022. Ebvallo represents a first-in-class allogeneic T-cell therapy, addressing a significant unmet need in a rare and aggressive cancer.
Atara Biotherapeutics (NASDAQ: ATRA) announced the grant of 8,000 restricted stock units to a newly hired employee. This stock award, approved by Atara's Compensation Committee, is part of the 2018 Inducement Plan, dated October 3, 2022. The units will vest over four years, with 25% vesting after the first year and the remaining in quarterly installments, contingent on ongoing employment. Atara continues to develop its T-cell immunotherapy platform aimed at treating serious diseases, including EBV-driven conditions.
Atara Biotherapeutics (NASDAQ: ATRA) has amended its collaboration agreement with Pierre Fabre, which includes a milestone payment of
FAQ
What is the current stock price of Atara Biotherape (ATRA)?
What is the market cap of Atara Biotherape (ATRA)?
What does Atara Biotherapeutics specialize in?
What is the focus of Atara’s product pipeline?
How does Atara differentiate itself from competitors?
What are Atara’s key collaborations?
What challenges does Atara Biotherapeutics face?
What is Tab-cel®?
What is ATA188, and what does it treat?
What diseases does Atara aim to address?
